Comments To FDA Suggest 510(k) Rescission Proposed Rule Needs Reworking
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed rule on 510(k) rescission does not provide an acceptable framework for appealing rescission and is untenable as it is currently written, industry comments recently submitted to FDA suggest.
You may also be interested in...
Predicate Device Removal May Trigger 510(k) Rescissions - Proposed Rule
FDA's Center for Devices and Radiological Health may rescind 510(k) clearance for a device if its predicate is removed from the market "for safety or effectiveness reasons" by either FDA or the product's manufacturer, the agency states in a Jan. 16 proposed rule.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.